BioMidwest
Filter News
Found 81,757 articles
-
Kindeva Drug Delivery Welcomes Jennifer Riter, New Vice President of Analytical Services
3/18/2024
Kindeva Drug Delivery, a global leader in drug-device combination products, welcomes Jennifer Riter as Vice President of Analytical Services to head up the recently announced analytical services global business unit.
-
Co-Diagnostics, Inc. CEO to Deliver Keynote Address at MarketsandMarkets 2024 in London, England
3/18/2024
Co-Diagnostics, Inc. announced that Co-Dx CEO Dwight Egan will deliver the keynote address at the 5th Annual Infectious Disease Diagnostics and Molecular Diagnostics Conference, organized by MarketsandMarkets and held March 21-22, 2024, in London, England.
-
Virtual Incision’s MIRA Surgical System to be Featured Among Elite AI-Enabled Innovations at NVIDIA GTC
3/18/2024
Virtual Incision Corporation, the developer of the MIRA Surgical System, announced the company will showcase MIRA at NVIDIA GTC.
-
New Research Shows the PrecivityAD2™ Blood Test Has High Accuracy Compared to Amyloid PET Scans in Individuals with Cognitive Impairment
3/18/2024
New research finds that C₂N Diagnostics, LLC’s proprietary algorithm used in its PrecivityAD2 blood test, which is used by healthcare providers to determine Alzheimer’s disease (AD) pathology in individuals with early cognitive impairment, can identify brain amyloid status with “sensitivity, specificity, positive and negative predictive values that approximate those of amyloid positron emission tomography (PET) imaging.”
-
Nexus Pharmaceuticals Launches Baclofen Injection, USP
3/18/2024
Today, Nexus Pharmaceuticals announced the launch of Baclofen Injection, USP.
-
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
3/18/2024
Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2023 and provided an update on progress toward achieving key corporate objectives.
-
Avenacy Announces New Product Launches and Participation in DCAT Week 2024
3/18/2024
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced it has launched Fosaprepitant for Injection and Fulvestrant Injection in the United States.
-
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
3/18/2024
Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, announced that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.
-
Otsuka and Lundbeck Present New Data Analyses on the Efficacy of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer’s Disease
3/18/2024
Otsuka and Lundbeck Present New Data Analyses on the Efficacy of REXULTI ® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer’s Disease.
-
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
3/18/2024
First Wave BioPharma, Inc., announced that two abstracts have been accepted for presentation at the 2024 Digestive Disease Week Conference taking place May 18-21, 2024, in Washington, D.C.
-
Lucas Vitale Joins Orthofix as Chief People and Business Operations Officer
3/18/2024
Orthofix Medical Inc., a leading global spine and orthopedics company, announced that Lucas Vitale has joined the company in the newly created role of Chief People and Business Operations Officer.
-
Phase III clinical trial of pediatric subjects with PMM2-CDG begins crossover to open label epalrestat
3/18/2024
Maggie's Pearl, a collaboration between Perlara, Maggie's Cure, and the Mayo Clinic, announced that the Phase III trial of oral epalrestat therapy in pediatric subjects with PMM2-CDG (formerly, Congenital Disorder of Glycosylation Type 1a) has been green-lighted to transition to open label.
-
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
3/18/2024
Oragenics, Inc. announced it has appointed Dr. James “Jim” Kelly, Neurologist, as its Chief Medical Officer, to oversee its upcoming Phase II clinical trial.
-
The American Cancer Society and Color Health Announce Expansion of a Comprehensive Cancer Care Solution
3/18/2024
The American Cancer Society and Color Health announced an expansion of their program to form a comprehensive cancer solution for employers and labor unions to support their employee and member populations across all stages of the cancer journey.
-
SHINE Technologies to Exhibit at 7th Annual Theranostics World Congress
3/18/2024
SHINE Technologies will showcase its innovative capabilities for producing non-carrier-added lutetium-177 (n.c.a Lu-177), a radioisotope used in targeted cancer treatments, at the 7th Theranostic World Congress (TWC), March 22-24 in Santiago, Chile.
-
Nortech Systems to Report Fiscal Fourth Quarter and Full Year 2023 Financial Results and Hold a Conference Call on March 20, 2024
3/18/2024
Nortech Systems Incorporated (Nasdaq: NSYS) will hold a live conference call and webcast at 4:00 p.m. Central Time on Wednesday, March 20, 2024, to discuss the company's fourth quarter financial results.
-
JanOne Regains Compliance with Nasdaq's Listing Requirements
3/15/2024
JanOne announced that on March 13, 2024 it received a notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market Inc. indicating that the Company had regained compliance with the minimum bid price requirement set forth in Rule 5550 of the Nasdaq Listing Rules.
-
Mesa Labs Releases Second Annual Responsible Business Program Brochure
3/15/2024
Mesa Laboratories, Inc. announced the release of its second annual Environmental, Social and Governance Program Brochure.
-
Dr. Jody Douglas Berry Joins NOWDiagnostics as Chief Scientific Officer
3/14/2024
NOWDiagnostics announced the appointment of Jody Douglas Berry, Ph.D. as chief scientific officer.
-
Aptar Pharma Continues Global Expansion with North America Capacity Extension at Congers, New York Site
3/14/2024
Aptar Pharma today announced the next phase of its global capacity expansion plan in North America, at its Aptar Congers, New York site.